Eligibility for potentially-curative surgery, regardless of previous neoadjuvant/pre-operative systemic treatment
Completed adequate pre-surgical staging procedures as per standard clinical practice
Diagnosis of one of the following:
Clinical Stage II or III breast cancer
Clinical Stage II or III NSCLC
HGSOC, either relapsed after primary treatment, confirmed by biopsy, or suspected on the basis of radiological criteria
Prostate cancer, with at least one of the following: Gleason Score ≥8, radiologically ≥cT2c, or PSA \>10
Gastric cancer with at least one of the following: Radiological/ecoendoscopic/laparoscopic evidence of node-positive disease, infiltration of the serosa or the surrounding organs, diffuse subtype as histology.
You may not be if
Unable to provide informed consent
Unable to undergo surgery
Radiological evidence of metastatic disease
Unwilling to be subjected to longitudinal plasma samples collection
Prior diagnosis of a malignant tumor for which the patients underwent any type of anti-neoplastic treatment within 2 years prior to the study screening
Clareo Health | Minimal Residual Disease in Solid Malignancies
